Acumen Pharmaceuticals (ABOS) Stock Forecast, Price Target & Predictions
ABOS Stock Forecast
Acumen Pharmaceuticals stock forecast is as follows: an average price target of $7.00 (represents a 195.36% upside from ABOS’s last price of $2.37) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
ABOS Price Target
The average price target for Acumen Pharmaceuticals (ABOS) is $7.00 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $7.00 to $7.00. This represents a potential 195.36% upside from ABOS's last price of $2.37.
ABOS Analyst Ratings
According to 7 Wall Street analysts, Acumen Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for ABOS stock is 0 'Strong Buy' (0.00%), 5 'Buy' (71.43%), 2 'Hold' (28.57%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Acumen Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 25, 2024 | David Hoang | Citigroup | $7.00 | $3.41 | 105.28% | 195.36% |
The latest Acumen Pharmaceuticals stock forecast, released on Jul 25, 2024 by David Hoang from Citigroup, set a price target of $7.00, which represents a 105.28% increase from the stock price at the time of the forecast ($3.41), and a 195.36% increase from ABOS last price ($2.37).
Acumen Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $7.00 |
| Last Closing Price | $2.37 | $2.37 | $2.37 |
| Upside/Downside | -100.00% | -100.00% | 195.36% |
In the current month, the average price target of Acumen Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Acumen Pharmaceuticals's last price of $2.37. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 03, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jul 25, 2024 | Citigroup | - | Buy | Initialise |
| May 18, 2023 | BTIG | - | Buy | Initialise |
| May 18, 2023 | Jefferies | - | Hold | Initialise |
| May 18, 2023 | Scotiabank | - | Sector Perform | Initialise |
| May 18, 2023 | Canaccord Genuity | - | Buy | Initialise |
| May 18, 2023 | Seaport Global | - | Buy | Initialise |
Acumen Pharmaceuticals's last stock rating was published by H.C. Wainwright on Oct 03, 2024. The company gave ABOS a "Buy" rating, the same as its previous rate.
Acumen Pharmaceuticals Financial Forecast
Acumen Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | $15.00M |
| High Forecast | - | - | - | - | - | - | - | $15.00M |
| Low Forecast | - | - | - | - | - | - | - | $15.00M |
| # Analysts | - | - | - | - | - | - | - | 2 |
| Surprise % | - | - | - | - | - | - | - | - |
Acumen Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ABOS's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Acumen Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 2 |
| EBITDA | - | - | - | - | - | - | - | $-18.45M |
| Avg Forecast | - | - | - | - | - | - | - | $10.44M |
| High Forecast | - | - | - | - | - | - | - | $10.44M |
| Low Forecast | - | - | - | - | - | - | - | $10.44M |
| Surprise % | - | - | - | - | - | - | - | -1.77% |
undefined analysts predict ABOS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Acumen Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
Acumen Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 2 |
| Net Income | - | - | - | - | - | - | - | $-16.50M |
| Avg Forecast | $-30.94M | $-32.14M | $-30.94M | $-29.44M | $-27.71M | $-21.73M | $-16.82M | $-16.45M |
| High Forecast | $-30.94M | $-32.14M | $-30.94M | $-28.24M | $-21.81M | $-21.73M | $-16.82M | $-13.61M |
| Low Forecast | $-30.94M | $-32.14M | $-30.94M | $-30.64M | $-35.97M | $-21.73M | $-16.82M | $-19.28M |
| Surprise % | - | - | - | - | - | - | - | 1.00% |
Acumen Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ABOS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Acumen Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 2 |
| SG&A | - | - | - | - | - | - | - | $5.15M |
| Avg Forecast | - | - | - | - | - | - | - | $13.46M |
| High Forecast | - | - | - | - | - | - | - | $13.46M |
| Low Forecast | - | - | - | - | - | - | - | $13.46M |
| Surprise % | - | - | - | - | - | - | - | 0.38% |
Acumen Pharmaceuticals's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to ABOS last annual SG&A of $5.15M (Dec 23).
Acumen Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 2 |
| EPS | - | - | - | - | - | - | - | $-0.28 |
| Avg Forecast | $-0.52 | $-0.54 | $-0.52 | $-0.49 | $-0.46 | $-0.36 | $-0.28 | $-0.27 |
| High Forecast | $-0.52 | $-0.54 | $-0.52 | $-0.47 | $-0.36 | $-0.36 | $-0.28 | $-0.23 |
| Low Forecast | $-0.52 | $-0.54 | $-0.52 | $-0.51 | $-0.60 | $-0.36 | $-0.28 | $-0.32 |
| Surprise % | - | - | - | - | - | - | - | 1.02% |
According to undefined Wall Street analysts, Acumen Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ABOS previous annual EPS of $NaN (undefined).
Acumen Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals | $0.34 | $3.67 | 979.41% | Buy |
| INZY | Inozyme Pharma | $2.79 | $14.67 | 425.81% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.37 | $7.00 | 195.36% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.62 | $38.80 | 184.88% | Buy |
| TERN | Terns Pharmaceuticals | $5.60 | $14.25 | 154.46% | Buy |
| MREO | Mereo BioPharma Group | $3.58 | $6.75 | 88.55% | Buy |
| AMLX | Amylyx Pharmaceuticals | $5.23 | $6.67 | 27.53% | Buy |
| HOOK | HOOKIPA Pharma | $2.72 | $3.00 | 10.29% | Buy |